‘…Solida-1 production plant will help us ensure that the results of scientific research are transformed into products as quickly as possible…’
Editorial image credit: Thomas Quack / Shutterstock
Bayer has unveiled its new Solida-1 pharmaceutical production facility located in Leverkusen, Germany. The company has said that the single-storey building will be one of the most modern pharmaceutical production plants in the world. Due to become operational during 2024 the facility, which cost €275 million, is part of a €1 billion investment program that Bayer is implementing to strengthen its pharmaceutical production network and the company’s in-house ‘innovation power.’ In addition, the facility will be at the centre of the company’s new global Centre of Excellence for the production of solid pharmaceutical products at the Leverkusen site. Products for the treatment of cancer and cardiovascular diseases will be among the pharmaceuticals manufactured.
As well as being part of Bayer Pharmaceutical’s strategy to improve therapeutic options available to patients, the new facility is also aligned with the company’s sustainability agenda where it is said to be setting new standards. The energy requirements are largely serviced by a geothermal plant which reduces the carbon dioxide emissions by 70%, compared with conventional systems. In addition, Solida-1 facilitates extensions, allowing flexibility to adapt to future developments in the pharmaceutical industry. The company said that the facility would also set new standards in digitalization.
Chairman of the Board of Management of Bayer AG, Werner Baumann said: ‘The construction of the new Solida-1 production plant will help us ensure that the results of scientific research are transformed into products as quickly as possible, thereby making a lasting improvement to patient’s lives.’